Drugs / TBP-PI-HBr
TBP-PI-HBr
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06727136 | Nov 2024 → Apr 2025 | — | Spero Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05856747 | May → Jun 2023 | — | Spero Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03395249 | Oct 2017 → Aug 2018 | — | Spero Therapeutics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06059846 | Dec 2023 → Jan 2025 | acute pyelonephritis | Spero Therapeutics | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBP-PI-HBr | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05856747 ↗ |
| Known as | SPR994 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03395249 ↗ |
| Known as | TBPM-PI-HBr | “Tebipenem pivoxil hydrobromide (TBPM-PI-HBr, formerly SPR994) is an orally available prodrug of tebipenem” PMID 31262768 ↗ Aug 2019 |
| Known as | Tebipenem pivoxil hydrobromide | “Tebipenem pivoxil hydrobromide (TBPM-PI-HBr, formerly SPR994) is an orally available prodrug of tebipenem” PMID 31262768 ↗ Aug 2019 |
| Modality | Small molecule | “a carbapenem with activity versus multidrug-resistant (MDR) Gram-negative pathogens” PMID 31262768 ↗ Aug 2019 |
| Route | Oral | “SPR994 is administered in tablet form orally.” NCT03395249 ↗ |